Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06749665
NA

Sclerotherapy and Candida Antigen in Treatment of Common Warts

Sponsor: Sohag University

View on ClinicalTrials.gov

Summary

This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.

Official title: Efficacy and Safety of Intralesional Injections of Candida Antigen, Polidocanol Sclerotherapy and Combined Candida Antigen With Polidocanol in Treatment of Patients With Common Warts

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2024-12-20

Completion Date

2025-12-01

Last Updated

2024-12-27

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

polidacanol 3%

Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany

BIOLOGICAL

candida antigen

delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart

Locations (1)

Sohag university hospital

Sohag, Egypt